Featured Publications
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.Peer-Reviewed Original ResearchConceptsAdvanced esophageal squamous cell carcinomaImmune checkpoint inhibitorsEsophageal squamous cell carcinomaSquamous cell carcinomaPD-L1 expressionKaplan-Meier curvesLow PD-L1 expressionFirst-line trialsProgression-free survivalDuration of responsePD-L1Overall survivalCell carcinomaRandomized clinical trialsPooled analysisClinical trialsCheckpoint inhibitorsTumor proportionEffect of immune checkpoint inhibitorsLow programmed death ligand 1Benefit of immune checkpoint inhibitorsHazard ratioSurvival dataFirst-line settingICI-based regimens
2023
2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Low Q, Looi W, Sukumar S, Ang Y, Wong A, Soo R, Sundar R, Lum J, Chee C, Bonney G, Tan H, Yong W. 2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma. Annals Of Oncology 2023, 34: s1170. DOI: 10.1016/j.annonc.2023.09.1310.Peer-Reviewed Original Research